Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

BACKGROUND: Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Boch, Tobias, Michaeli, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338124/
https://www.ncbi.nlm.nih.gov/pubmed/35819632
http://dx.doi.org/10.1007/s40261-022-01173-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338124/
https://www.ncbi.nlm.nih.gov/pubmed/35819632
http://dx.doi.org/10.1007/s40261-022-01173-3

Ejemplares similares